chloramphenicol has been researched along with raltegravir in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bode, ML; Coyanis, EM; Mosebi, S; Njengele, Z; Rashamuse, TJ; Sayed, Y | 1 |
1 review(s) available for chloramphenicol and raltegravir
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for chloramphenicol and raltegravir
| Article | Year |
|---|---|
Design, synthesis and biological evaluation of novel 2-(5-aryl-1H-imidazol-1-yl) derivatives as potential inhibitors of the HIV-1 Vpu and host BST-2 protein interaction.
Topics: Anti-HIV Agents; Antigens, CD; Cell Line; Drug Design; GPI-Linked Proteins; HIV-1; Human Immunodeficiency Virus Proteins; Humans; Imidazoles; Microbial Sensitivity Tests; Protein Multimerization; Viral Regulatory and Accessory Proteins; Virus Replication | 2020 |